SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over the next 12 months.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe